As early as the 1990s, researchers realized that CD7 might contribute to the pathogenesis of rheumatic diseases, and the effect of monoclonal antibody to CD7 on rheumatic diseases was also evaluated in the clinical setting [40]. The gene discussed is CD7; the disease is rheumatic disorder.